Сложности подбора антигипертензивной терапии у пожилых: о чем нужно помнить клиницисту?

1. Chaudhry KN, Chavez P, Gazowsky J et al. Hypertension in the elderly: some practical considerations. Clev Clin J Med 2012; 79 (10): 694–704.
2. Messerli FH, Sundgaard-Riise K, Ventura HO et al. Essential hypertension in the elderly: heamodynamics, intravascular volume, plasma renin activity, and circulating catecholamine levels. Lancet 1983; 2: 983–6.
3. Staessen JA, Gazowsky J, Wang JG et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865–72.
4. Schall P, Wehling M. Treatment of arterial hypertension in the very elderly: a meta-analysis of clinical trials. Arzneimittelforschung 2011; 61: 221–8.
5. Beckett NS, Peters R, Fletcher AE et al. HYVET study group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–98.
6. Aronov WS, Fleg JL, Pepine CJ et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventing Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Soc Hypertens 2011; 5: 259–352.
7. Bray GA, Vollmer WM, Sacks FM et al. DASH Collaborative Research Group. A further subgroup analysis of the effects of the DASH diet and three dietary sodium levels on blood pressure: results of the DASH-Sodium trial. Am J Cardiol 2004; 94: 222–7.
8. Frisoli TM, Schmieder RE, Grodzicki T, Messerli FH. Salt and hypertension: is salt dietary reduction worth the effort? Am J Med 2012; 125: 433–9.
9. Родионов А.В. Нестероидные противовоспалительные препараты и артериальная гипертензия: актуальность проблемы и тактика ведения пациентов. Лечащий врач. 2013; 2: 1–7.
10. Viera AJ, Neutze DM. Diagnosis of secondary hypertension: an age-based approach. Am Fam Physician 2010; 82: 1471–8.
11. Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347–51.
12. Watfa G, Rossignol P, Kearney-Schwartz A et al. Use of calcium channel blockers is associated with better cognitive performance in older hypertensive patients with subjective memory complaints. J Hypertens 2010; 28: 2485–93.
13. Ohrui T, Tomita N, Sato-Nakagawa T et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004; 63: 1324–5.
14. Borghi C. Lercanidipine in hypertension. Vasc Health Risk Man 2005; 1 (3): 173–82.
15. Calvo C, Hermida RC, Navarro A. Treatment of elderly hypertensive patients. Preliminary results from the zanycal study. Am J Hypertens 2002; 15: 110A.
16. Martell N, Lopez-Eady MD, Castro P et al. Modifications of the pulse pressure in elderly hypertensives treated with lercanidipine. J Hypertens 2004; 22 (Suppl. 2): S121.
17. Roma J, Sobrino J, Soler-Amigo J et al. Treatment with lercanidipine during six months in hypertensive elderly patients (more than sixty years). J Hypertens 2004; 20 (Suppl. 4): S391.
18. Leonetti G, Magnani B, Pessina AC et al. Tolerability of long-term treatment wth lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15: 932–40.
19. Cherubini A, Fabris F, Ferrari E et al. Comparative effects of lercanidipine, lacidipine and nifedipine gastrointestinal therapeutic system on blood pressure and heart rate in elderly hypertensive patients: the ELderly and LErcanidipine (ELLE) study. Arch Gerontol Geriatr 2003; 37: 203–12.
20. Barbagallo M, Barbagallo SG. Efficacy and tolerability of lercanidipine in monotherapy of elderly patients with isolated systolic hypertension. Aging (Milano) 2000; 12: 375–9.
21. Millar-Craig M, Shaffu B, Greenough A et al. Lercanidipine vs lacidipine in isolated systolic hypertension. J Hum Hypertens 2003; 17: 799–806.
22. Borghi C, Prandin MG, Dormi et al. Improved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trial. Blood Press 2003; Suppl. 1: 14–21.

Д.А.Напалков 

ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М.Сеченова Минздрава РФ